ASP Isotopes Inc. (NASDAQ:ASPI – Get Free Report) Director Michael Gorley sold 30,000 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $6.27, for a total transaction of $188,100.00. Following the sale, the director directly owned 87,908 shares in the company, valued at approximately $551,183.16. This trade represents a 25.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
ASP Isotopes Stock Performance
ASP Isotopes stock traded down $0.05 during mid-day trading on Wednesday, reaching $6.17. The company’s stock had a trading volume of 3,923,284 shares, compared to its average volume of 4,990,399. The company has a market capitalization of $776.80 million, a P/E ratio of -2.97 and a beta of 3.51. ASP Isotopes Inc. has a 12-month low of $3.92 and a 12-month high of $14.49. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.37 and a current ratio of 4.39. The firm’s fifty day moving average price is $6.24 and its two-hundred day moving average price is $5.90.
ASP Isotopes (NASDAQ:ASPI – Get Free Report) last issued its earnings results on Wednesday, May 20th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.06. The business had revenue of $8.36 million during the quarter, compared to the consensus estimate of $3.68 million. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
ASPI has been the subject of several recent analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a research note on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.00.
Get Our Latest Stock Report on ASPI
About ASP Isotopes
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Further Reading
- Five stocks we like better than ASP Isotopes
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for ASP Isotopes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASP Isotopes and related companies with MarketBeat.com's FREE daily email newsletter.
